Skip to main content
Shenzhen Salubris Pharmaceuticals Co., Ltd. logo

Shenzhen Salubris Pharmaceuticals Co., Ltd. — Investor Relations & Filings

Ticker · 002294 ISIN · CNE100000FW8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,658 across all filing types
Latest filing 2026-06-04 Transaction in Own Shar…
Country CN China
Listing Shenzhen Stock Exchange 002294

About Shenzhen Salubris Pharmaceuticals Co., Ltd.

https://www.salubris.com

Shenzhen Salubris Pharmaceuticals Co., Ltd. is a research-driven enterprise focused on the development, manufacturing, and commercialization of innovative drugs and medical devices. The company specializes in therapeutic areas including cardiovascular diseases, chronic kidney disease, and metabolic disorders. Its product portfolio features proprietary treatments such as Allisartan Isoproxil for hypertension and Clopidogrel Bisulfate for anti-platelet therapy. Salubris maintains an integrated value chain encompassing research and development, active pharmaceutical ingredient production, and finished dosage manufacturing. The firm emphasizes innovation through its dedicated R&D centers and strategic focus on biologics and small molecule drugs, aiming to provide comprehensive clinical solutions for chronic conditions.

Recent filings

Filing Released Lang Actions
关于回购股份事项前十名股东及前十名无限售条件股东持股情况的公告
Transaction in Own Shares Classification · 95% confidence The document is an official announcement by Shenzhen Salubris Pharmaceuticals concerning a share repurchase (“回购股份事项”) and discloses the top ten shareholders and top ten unrestricted shareholders as of the record date. This clearly relates to the company’s own share transaction (share buyback). According to the filing definitions, such announcements fall under Transaction in Own Shares (Code: POS).
2026-06-04 Chinese
关于JK06境外临床试验进展的公告
Regulatory Filings Classification · 88% confidence The document is a corporate announcement (“公告”) detailing the clinical trial progress of the drug candidate JK06. It contains no financial statements, no board or management changes, no earnings or dividend information, no share transactions, and no merger or financing activity. It is an operational update on clinical trial data and falls under miscellaneous regulatory announcements that do not fit other specific categories. Therefore, it should be classified as a Regulatory Filing (RNS).
2026-06-02 Chinese
第六届董事会第十九次会议决议公告
Transaction in Own Shares Classification · 92% confidence The document is a board resolution announcement detailing the company’s share repurchase plan, including authorization, price, volume, and timetable. It is not a financial report, AGM materials, or regulatory certification. It specifically describes a transaction in the company’s own shares (stock buyback). According to the filing definitions, such announcements fall under Transaction in Own Shares (Code: POS).
2026-06-01 Chinese
关于控股股东部分股份质押及解除质押的公告
Regulatory Filings Classification · 75% confidence The document is a regulatory disclosure by Shenzhen Xintai Pharmaceutical Co., Ltd. detailing pledge and release of share pledges by its controlling shareholder. It is not an Annual Report, earnings release, or management presentation. It is not a tender offer or acquisition, nor a dividend or governance statement. It is also not the company buying back its own shares, nor a threshold crossing of ownership. It is a mandated securities exchange announcement of a shareholder’s pledge transactions, falling under general regulatory filings. Thus, it is classified as a Regulatory Filing (RNS).
2026-05-29 Chinese
关于SAL0195药品临床试验申请获得受理的公告
Regulatory Filings Classification · 85% confidence The document is a Chinese company announcement regarding regulatory approval to accept a clinical trial application for a new drug (SAL0195). It does not contain substantive financial data, nor does it announce dividends, share issues, director changes, or earnings. It is a compliance/announcement with a government agency (National Medical Products Administration), fitting best into the generic “Regulatory Filings” category as a miscellaneous regulatory announcement. Therefore, it should be classified as RNS.
2026-05-21 Chinese
关于第三期员工持股计划第二个锁定期延长的公告
Share Issue/Capital Change Classification · 70% confidence The document is a formal announcement by Shenzhen Xintai Pharmaceutical Co. Ltd. regarding the extension of the second lock-up period under its third employee stock ownership plan. It does not contain financial statements or serve as a management discussion, nor is it a board change or earnings release. It is an amendment to the company’s capital structure via employee share plan, which aligns with the “Share Issue/Capital Change” category for announcements about share plan adjustments and capital changes.
2026-05-14 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.